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INTRODUCTION
Hepatocellular carcinoma (HCC) remains one of the
most common tumours in the world with an incidence as
high as 30 per 100,000 population in endemic regions.1
In recent years, the incidence of HCC has been on the
rise, due to a variety of factors including the increasing
incidence of hepatitis C infection. Despite the many
treatment modalities available, HCC continues to be
associated with a poor prognosis and has an overall
5-year survival of < 5%.2 Only surgery, be it liver resection
or transplantation, offers a chance of long-term, disease-
free survival.3
LIVER TRANSPLANTATION
Liver transplantation is the most radical form of surgical
treatment available for HCC. Not only does it remove the
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tumour but it also replaces the underlying diseased liver
parenchyma. Transplantation removes all the cirrhotic
tissue that is at risk for tumour formation and potentially
all occult microscopic foci of tumour cells within the
diseased liver, which are the main source for tumour
recurrence. It also overcomes the limitations of operating
in a patient with inadequate liver reserve and, thus, avoids
the potential complications of postoperative liver failure.4
Liver transplantation was first performed for liver
malignancy in the 1960s. In fact, five of the first six
liver transplants performed in the United States and two
of the first three performed in the United Kingdom, were
for patients with primary liver malignancies.5,6
Nonetheless, this initial enthusiasm was dampened by
poor results. The perioperative mortality was high, in the
order of 24% to 70%.6 Due to poor patient selection,
the tumour recurrence rate was also unacceptably high.
This resulted in 3-year and 5-year survival rates of 15%
to 37%  (Table 1).7–12 Fewer than 10% of patients were
tumour-free for more than 2 years.12
The high perioperative mortality and tumour
recurrence rates coupled with the high costs and
limited supply of donor organs inevitably led to
questions regarding the role of liver transplantation for
HCC. In Europe, the percentage of liver transplants
performed for a malignant indication decreased from
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29% between 1983 to 1988, and 10% between 1989 and
1992.13
The early results for transplanting patients with HCC
were not uniformly dismal. A good outcome was often
noted when patients with “incidental” tumours were
transplanted.7 The recurrence rate in these patients was
lower (0%–13%) compared to patients with HCC
diagnosed before transplantation (37%–82%).9,14
In a subgroup of cirrhotic patients with no “adverse”
factors, transplantation yielded superior results compared
to resection. In a retrospective analysis of 60 patients,
Bismuth et al showed that patients with tumours less than
3 cm in diameter, fewer than 3 nodules and without
extrahepatic disease had an 83% 3-year survival after
transplantation, compared to 18% in the resection
group.15 When the same centre used the above prognostic
criteria to select patients for transplantation, they found
that survival results improved (5-year survival rate of
73%) in the entire transplanted patient cohort studied.4
Favourable prognostic features have since been identified
that yield a better outcome after transplantation.14–22
These are summarized in Table 2.
With careful selection using the above prognostic
criteria, patients transplanted for HCC have results as
favourable as transplantation for non-malignant
indications (Table 3).4,23,24 Today, liver transplantation is
no longer considered an experimental form of treatment
but is an established therapeutic modality for HCC.
LIMITATIONS FOR TRANSPLANTATION IN PATIENTS
WITH HCC IN ASIA
Most of  the recommendations advocating
transplantation as treatment for HCC originated from
established liver transplant centres in Europe or the
United States. In some of these centres, transplantation
has surpassed resection as the treatment of choice in
cirrhotic patients with a small HCC and well-preserved
liver function.24 This approach is supported by intention-
to-treat analyses, which suggest that surgical resection
and transplantation have at least similar survival rates in
patients with no adverse prognostic factors.25 Nonetheless,
this relies heavily on the premise that there is early
availability of donor organ grafts.
The situation in Asia is entirely different from that in
the West. Liver transplantation is not available in many
Asian countries, as the costs associated with establishing
a transplant service and the treatment itself are too
high. Even in countries where liver transplantation is
available, only limited subsidies are available to support
the financially needy patient with a medical indication
for transplantation. In Singapore, only a limited number
of transplants are subsidized each year by the govern-
ment. In Japan, no insurance subsidization is available
for transplantation in patients with hepatitis B or C viral
infection. Because the majority of the patients with HCC
in Japan are carriers of viral hepatitis antigens, transplan-
tation is rarely offered as a treatment option.
Although a universal problem, donor liver shortage is
particularly acute in Asia for various cultural, religious
Table 1. Early results of transplantation for hepatocellular carcinoma
Operative Survival
Ref. Study Year Patients mortality Recurrence 1 year 3 years 5 years
(%) (%)  (%)  (%)  (%)
7 Iwatsuki (Pittsburgh, USA) 1985 37 24 (at 30 days) 43 68 25 –
8 Bismuth (Paris, France) 1987 157 – – 31 – –
 9 O’Grady (King’s College, UK) 1988 19 31 (at 90 days) 65 43 37 37
10 Ringe (Hannover, Germany) 1989 79 30 52 38 15 15
11 Penn  (multicentre) 1991 365 – 39 – – 18
12 Dalgic (Birmingham, UK) 1994 39 28 46 56 32 26
Table 2. Prognostic features for transplantation in
patients with hepatocellular carcinoma
Small, solitary lesion < 5 cm in diameter
3 nodules, each less than 3 cm in diameter
No vascular or lymphatic invasion
No extrahepatic disease
– = no data.
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and social reasons. In Singapore, of the first nine patients
transplanted for HCC over a 5-year period, the median
waiting period was 5 months. Two of these patients had
a waiting time of 12 months. In a decision analysis model
for patients with compensated liver cirrhosis and
surgically-resectable HCC, Sarasin et al showed that
when the length of the waiting period for a liver graft
exceeded an average of 8 months, the survival benefit
provided by liver transplantation is overwhelmed by the
risk of tumour growth and dissemination.26 This would
lead to a potential “drop-out” rate as high as 25% for
patients with HCC initially accepted for transplantation.
Our experience supports this conclusion, with more than
40% of patients on the waiting list “dropping out” due to
worsening of their clinical condition or tumour
dissemination. To alleviate the problems associated with
donor organ shortage, attempts have been made to use
grafts from less traditional sources. As in the West, these
include the use of marginal donors, the second graft
arising from split liver transplant retrievals and living
donors. Nonetheless, it is only living donor liver
transplantation (LDLT) that is likely to have a significant
impact in alleviating this shortage of donor organs.
Today, LDLT constitutes a significant proportion of
the liver transplants performed in Asia. In Hong Kong,
Japan, Korea, Taiwan and Singapore, LDLT is offered
routinely as a therapeutic option to patients with end-
stage liver disease. LDLT constitutes 30% of liver
transplants performed in our institution; this includes two
of the 16 patients transplanted for HCC. Nonetheless,
problems remain in the use of such grafts. Not all potential
living donors are suitable and as many as one-third may
be rejected due to blood group incompatibility, unsuitable
donor liver, as well as high risk to the donor from
inadequate liver volume and concomitant medical
disease.27 LDLT has real risks and potential complications
for the donor. As the minimum graft volume represents
40% of the standard liver volume of the recipient,28 a
donor left hepatectomy, right hepatectomy or even an
extended right hepatectomy is often required in order to
provide sufficient liver function for an adult recipient.28,29
Donor complications have included bleeding, liver
dysfunction and failure, biliary complications and even
death.27,29–32 Subjecting a healthy donor to such a major
operation with potentially disastrous complications has
raised ethical concerns.31 It is mandatory that such a
strategy should only be undertaken by liver transplant
centres highly experienced in both transplant and non-
transplant related hepatic surgery. The potential living
donor should also be fully counseled concerning the risks
involved in the operation.
TREATMENT STRATEGIES FOR HCC IN ASIA IN THE
ERA OF LIVER TRANSPLANTATION
In treating patients with HCC, the ideal therapeutic
modality is one that provides the lowest immediate
mortality and the longest possible tumour-free survival,
after considering factors like tumour location and
distribution, liver reserve and co-morbid disease.33
Nonetheless, different strategies have been developed
in the West and in Asia. The problem of severe donor
liver shortage favours the use of resection for patients
with easily accessible tumours and good liver synthetic
function, in whom the risk of resection is relatively
low.20,34 Liver transplantation has no significant
role for these patients in Asia, in contrast to that in the
West.24,25
Resection is generally safe in patients with good liver
synthetic function and no significant portal hypertension.
With advances made in surgical techniques, perioperative
mortality has decreased significantly from 28% to 0% in
the hands of experienced hepatobiliary surgeons.35 Most
liver centres report perioperative mortality rates in the
Table 3. Improved results with strict inclusion criteria when transplanting for hepatocellular carcinoma
Operative Survival
Ref. Study Year Patients mortality Recurrence 1 year 3 years 5 years
(%) (%)  (%)  (%)  (%)
4 Bismuth (Paris, France) 1999 45 24 (at 30 days) 43 68 25 –
23 Bechstein (Berlin, Germany) 1998 52 3.8 (at 2 months) 21 88 80 71
24 Figueras (Barcelona, Spain) 2000 85 – – 84 74 60
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order of 5% to 10%.3,36 Resection is particularly indicated
in patients who present with large tumours and good liver
reserve.37 With strict inclusion criteria, such patients
would not be offered liver transplants, even in the West.
Unfortunately, not more than 20% of patients with
HCC are suitable candidates for resection.3,38,39 Liver
transplantation should then be offered to the patients
with “small volume” HCC (< 5 cm in diameter and < 3
nodules in number) complicated by compromised liver
reserve. In these instances, only liver transplantation can
potentially cure the two disease processes, that of
malignancy and cirrhosis. For the remaining patients in
whom surgery is contraindicated, a variety of local
ablative treatment strategies are available such as
transarterial chemoembolization (TACE), percutaneous
ethanol injection (PEI), cryotherapy, radiofrequency
ablation and internal radiation. Palliative combination
systemic chemotherapy has been given with mixed results.
The treatment strategy adopted at the National University
Hospital, Singapore is shown in the Figure.
PREVENTING TUMOUR PROGRESSION IN PATIENTS
AWAITING LIVER TRANSPLANTATION
The long waiting period for a suitable donor liver has
prompted many centres to offer adjuvant therapy to
patients with HCC awaiting a liver transplant. This includes
the use of TACE and/or systemic chemotherapy. It is
hoped that this may prevent tumour progression in patients
enduring the long wait for a liver graft and also decrease
the risk of tumour cell spillage during transplantation.25,40
Based on data derived from non-transplanted patients
with HCC, TACE has been reported as an effective means
of tumour control while awaiting liver transplantation.
Various authors have reported TACE to be effective in
inducing marked tumour necrosis with only minor adverse
sequelae,41–43 although there is no evidence of better
long-term survival in any randomized, controlled trial to
date.44–49
TACE has been shown to offer a survival advantage in
a subgroup of patients with tumours more than 3 cm in
Figure. Treatment strategy for hepatocellular carcinoma at National University Hospital, Singapore. TACE = transarterial
chemoembolization; RF = radio frequency; PEI = percutaneous ethanol injection.
Hepatocellular carcinoma diagnosed
No
•  Anatomically resectable?
•  Good liver function (Child’s A)?
Satisfies selection criteria for liver transplant?
•  Less than 3 nodules, each with diameter < 3 cm
•  Solitary nodule < 5 cm diameter
•  No extrahepatic disease
•  No medical contraindication to liver transplantation
Consider palliative treatments
•  Ablative therapy (cryotherapy,
    RF ablation, PEI)
•  Chemotherapy
•  Other investigational treatments
Consider preoperative
TACE while on waiting list
Liver resection
Liver transplantation
➪
➪
➪
Yes
No
➪
Yes
➪
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size. A 74% disease-free survival rate at 5 years was
similar to that of patients with smaller tumours who
underwent liver transplantation.48 This raises the
possibility of TACE being used to downstage tumours
and, thus, expand the selection criteria for transplantation.
In view of our potentially long waiting period for a
suitable donor graft, we routinely offer TACE to our
patients with HCC awaiting transplantation. Twelve of
our 16 patients with HCC underwent TACE pre-
operatively; this was repeated every 3 to 6 months until
they received a liver graft. Three patients were not given
TACE, as they underwent transplantation soon after being
placed on the waiting list, or in the context of a living
related transplant. In one patient, HCC was diagnosed
incidentally after histological examination of the explanted
liver post-transplantation.
Although systemic chemotherapy has been used
to complement liver transplantation in some centres,
there are few data from prospective controlled trials to
support its adoption perioperatively. Some authors have
suggested some efficacy in the context of large, high-risk
tumours.43,50 Nonetheless, these same patients would
not fulfill the strict selection criteria generally adopted for
transplantation. The use of systemic chemotherapy in
this setting is, therefore, considered investigational.
SUMMARY
Today, liver transplantation is an established treatment
modality for patients with HCC, allowing a potential for
disease-free, long-term survival. It complements the
therapeutic armamentarium of the hepatobiliary surgeon
and has a distinct benefit in the subgroup of patients with
small tumour burdens and inadequate liver reserves to
tolerate resection.
In Asia, for the patient with HCC and good liver
functional reserve, resection remains the treatment of
choice, as the severe shortage of donor liver limits the
application of transplantation. The use of marginal donors,
split liver grafts and grafts from living donors will help
alleviate the problem of organ shortage but are best
performed in experienced liver transplant centres to
ensure the best possible outcomes. Ethical issues related
to the use of LDLT for the treatment of adult patients with
HCC remain to be addressed. The role of therapies to
limit tumour progression during the waiting period needs
to be further investigated in the setting of a prospective
trial and their benefits better defined.
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